CLL

expert roundtables

by Matthew S. Davids, MD, MMSc; Susan O'Brien, MD; and William G. Wierda, MD, PhD

Bruton tyrosine kinase (BTK) inhibitors have helped to revolutionize the treatment of chronic lymphocytic leukemia (CLL). Investigations into new a......READ MORE

expert roundtables

by Matthew S. Davids, MD, MMSc; Susan O'Brien, MD; and William G. Wierda, MD, PhD

There are important patient- and disease-related factors that are useful for guiding treatment regimen selection in patients with chronic lymphocyt......READ MORE

patient care perspectives

by William G. Wierda, MD, PhD

The first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly effective in the treatment of chronic lymphocytic leukemia (CLL), b......READ MORE

patient care perspectives

by Matthew S. Davids, MD, MMSc

Given the growing number of treatment options for chronic lymphocytic leukemia (CLL), the selection of first-line therapy requires an in-depth conv......READ MORE

clinical topic updates

by Susan O’Brien, MD

Continuous therapy with Bruton tyrosine kinase (BTK) inhibitors and fixed-duration regimens (eg, venetoclax/obinutuzumab) are effective as first-li......READ MORE